Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

June 30, 2006

Study Completion Date

November 30, 2007

Conditions
Lymphatic Malformations
Interventions
DRUG

picibanil

Up to .2 mg per injection, given intralesionally every 6-8 weeks

Trial Locations (13)

13210

SUNY Upstate Medical University, Syracuse

23507

Children's Hospital of the Kings Daughter, Norfolk

33701

All Children's Hospital, St. Petersburg

52242

University of Iowa Hospitals and Clinics, Iowa City

53201

Children's Hospital of Wisconsin, Milwaukee

55404

Children's Hospitals and Clinics - Minneapolis, Minneapolis

77030

Texas Pediatric Otolaryngology Center, Houston

80218

Children's Hospital of Denver, Denver

92123

Children's Associated Medical Group, San Diego

Unknown

Childrens National Medical Center, Washington D.C.

Oregon Health Sciences University, Portland

Vanderbilt University, Nashville

53792-0001

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
lead

University of Iowa

OTHER

NCT00010452 - Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations | Biotech Hunter | Biotech Hunter